Icon (NASDAQ:ICLR - Get Free Report) posted its earnings results on Wednesday. The medical research company reported $3.26 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.18 by $0.08, Briefing.com reports. Icon had a return on equity of 10.94% and a net margin of 9.82%. The firm had revenue of $2.02 billion for the quarter, compared to analyst estimates of $1.98 billion. During the same quarter in the prior year, the company earned $3.75 EPS. Icon's revenue was down 4.8% on a year-over-year basis. Icon updated its FY 2025 guidance to 13.000-14.000 EPS.
Icon Price Performance
Shares of NASDAQ ICLR traded down $8.00 during mid-day trading on Friday, reaching $187.01. 1,594,826 shares of the company traded hands, compared to its average volume of 1,325,979. Icon has a fifty-two week low of $125.10 and a fifty-two week high of $338.67. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.27 and a quick ratio of 1.27. The firm has a market cap of $15.10 billion, a PE ratio of 19.24, a price-to-earnings-growth ratio of 2.53 and a beta of 1.17. The stock has a fifty day simple moving average of $143.46 and a 200-day simple moving average of $164.43.
Wall Street Analyst Weigh In
A number of research analysts have weighed in on the company. Evercore ISI increased their price target on Icon from $170.00 to $240.00 and gave the stock an "outperform" rating in a research note on Friday. UBS Group increased their price target on Icon from $170.00 to $240.00 and gave the stock a "buy" rating in a research note on Friday. TD Cowen lowered Icon from a "buy" rating to a "hold" rating and reduced their price target for the stock from $254.00 to $157.00 in a research note on Monday, April 14th. Robert W. Baird upgraded Icon from a "neutral" rating to an "outperform" rating and upped their price objective for the stock from $150.00 to $224.00 in a report on Thursday. Finally, Truist Financial lifted their target price on Icon from $187.00 to $234.00 and gave the company a "buy" rating in a report on Friday. Seven equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, Icon has a consensus rating of "Moderate Buy" and a consensus price target of $219.54.
Get Our Latest Stock Analysis on ICLR
About Icon
(
Get Free Report)
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Featured Articles
Before you consider ICON, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ICON wasn't on the list.
While ICON currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
